RE: Research News: Potential Cancer Treatments Through Inhibiting HER Kinase
Thanks for sharing this interesting research news..just read the full paper. I found that the efficacy of neratinib is not that great in comparison to other approved therapies (targeting oncogenic alterations in EGFR, ALK, ROS1 and BRAF ) and may not work as a good monotherapy to treat wide variety of HER2- and HER3-mutant cancers. The well-know problem with neratinib is it induces serious diarrhea in patients. Thats why they are required to give mandatory anti-diarrhoeal prophylaxis with neratinib. But hey every drugs have their good and bad sides in terms of side effects and efficacy.
Neratinib was recently approved by FDA to prevent recurrence of early-stage HER2-positive breast cancer. Neratinib HER Mutation Basket Study (SUMMIT) looks like a very promising phase II clinical trial to watch closely for and its future strategy to go into Phase III trial. There is certainly a promise for this work to move forward if novel combination of neratinib with other less toxic anti-cancer drug is used. Using neratinib as a monotherapy would be a hard sell. Just my opinion after looking at the data and following the discussion of authors. Cheers to science!
Yep, I made a point to mention that they stated this, but they also mentioned its potential in use in combination therapy with other HER inhibitors. So it could still find a way to prove more useful then traditional therapies yet, onward for more research.
For clarity I mentioned this in the following paragraph:
Indeed, its just not efficacious enough. However, I think the more important information here came from the identification of a whole host of new information on which HER mutations are gain of function. This will allow for a better, more targeted application of inhibitors to those people with cancers having these gain of function mutations.
Thanks for clarifying. I was skimming through. I forwarded this nature paper to my PhD friend who works on protein engineering to enhance the efficacy of HER-targeted therapeutics. I will point this post to him. Looking forward for your research news series.
Thanks, I was trying to write this for a slightly more general audience. Your friend would likely get much more out of the original research article then my small discussion about it :)